| Code | CSB-RA614514MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Camoteskimab, targeting interleukin-18 (IL-18), a pro-inflammatory cytokine belonging to the IL-1 superfamily. IL-18 plays a critical role in both innate and adaptive immune responses by promoting interferon-gamma production and enhancing natural killer cell and T-cell activity. Dysregulated IL-18 signaling has been implicated in various inflammatory and autoimmune conditions, including adult-onset Still's disease, hemophagocytic lymphohistiocytosis, rheumatoid arthritis, and inflammatory bowel disease. Elevated IL-18 levels are also associated with metabolic disorders and certain malignancies, making it an important therapeutic target.
Camoteskimab is a clinical-stage therapeutic antibody designed to neutralize IL-18 activity and has shown promise in treating conditions characterized by excessive IL-18-driven inflammation. This biosimilar antibody provides researchers with a valuable tool for investigating IL-18-mediated pathways, studying inflammatory disease mechanisms, and exploring potential therapeutic interventions in preclinical models. It supports investigations into cytokine biology, immune regulation, and the pathophysiology of IL-18-associated disorders.
There are currently no reviews for this product.